Stay updated with breaking news from Johannes nippgen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
June 07, 2021 SUZHOU, China, June 7, 2021 /PRNewswire/ Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) is presented in a poster session at the ASCO 2021 (2021 American Society of Clinical Oncology Annual Meeting). Esophageal cancer is one of the most common malignant tumors in the world. According to data released by GLOBOCAN 2020, approximately 320,000 new cases occurred in China in 2020, accounting for half of the global new cases, of which esophageal squamous cell carcinoma (ESCC) is the main subtype (90%-95%). The prognosis of esophageal cancer is very poor, with only about 20% overall 5-year survival rate and 3.5% 5-year survival rate for metastatic patients. There is a huge unmet clinical need. KN046-204 is a phase II clinic ....
Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.